Multi-Biomarker Profiling and Recurrent Hospitalizations in Heart Failure

Frontiers in Cardiovascular Medicine

Volumn 3, Issue , 2016, Pages

  Bayes Genis, Antoni ^a,b   Núñez, Julio ^c,d   Núñez, Eduardo ^c   Martínez, Jaume Barallat ^a   Ferrer, Maria Cruz Pastor ^a   de Antonio, Marta ^a   Zamora, Elisabet ^a,b   Sanchis, Juan ^c,d   Rosés, Josep Lupón ^a,b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d UNIVERSITY OF VALENCIA   (Spain)

Author keywords

biomarkers; heart failure; hospitalizations; hs TnT; NT proBNP; prediction; ST2

Indexed keywords

EID: 85013696051     PISSN: None     EISSN: 2297055X     Source Type: Journal    
DOI: 10.3389/fcvm.2016.00037     Document Type: Article

References (26)

1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. American Heart Association Statistics Committee and Stroke Statistics – 2016 update: a report from the American Heart Association. Circulation (2015) 133:e38–360.10.1161/CIR.0000000000000350
2. Krumholz HM, Merrill AR, Schone EM, Schreiner GC, Chen J, Bradley EH, et al. Patterns of hospital performance in acute myocardial infarction and heart failure 30-day mortality and readmission. Circ Cardiovasc Qual Outcomes (2009) 2:407–13.10.1161/CIRCOUTCOMES.109.88325620031870
3. Dunlay SM, Redfield MM, Weston SA, Therneau TM, Hall Long K, Shah ND, et al. Hospitalizations after heart failure diagnosis: a community perspective. J Am Coll Cardiol (2009) 54:1695–702.10.1016/j.jacc.2009.08.019
4. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med (2014) 371:993–1004.10.1056/NEJMoa140907725176015
5. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med (2009) 361:1329–38.10.1056/NEJMoa090643119723701
6. Anker SD, McMurray JJ. Time to move on from ‘time-to-first’: should all events be included in the analysis of clinical trials? Eur Heart J (2012) 33:2764–5.10.1093/eurheartj/ehs277
7. Rogers JK, Jhund PS, Perez A-C, Böhm M, Cleland JG, Gullestad L, et al. Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA trial (Controlled Rosuvastatin Multinational Trial in Heart Failure). JACC Heart Fail (2014) 2:289–97.10.1016/j.jchf.2013.12.00724952697
8. Gaggin HK, Januzzi JL, Jr. Natriuretic peptides in heart failure and acute coronary syndrome. Clin Lab Med (2014) 34:43–58.10.1016/j.cll.2013.11.00724507786
9. Gualandro DM, Puelacher C, Mueller C. High-sensitivity cardiac troponin in acute conditions. Curr Opin Crit Care (2014) 20:472–7.10.1097/MCC.000000000000013225159476
10. Daniels LB, Bayes-Genis A. Using ST2 in cardiovascular patients: a review. Future Cardiol (2014) 10:525–39.10.2217/fca.14.3625301315
11. Bayes-Genis A, de Antonio M, Galán A, Sanz H, Urrutia A, Cabanes R, et al. Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. Eur J Heart Fail (2012) 14:32–8.10.1093/eurjhf/hfr15622179033
12. Pascual-Figal DA, Manzano-Fernández S, Boronat M, Casas T, Garrido IP, Bonaque JC, et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail (2011) 13:718–25.10.1093/eurjhf/hfr04721551163
13. Ahmad T, Fiuzat M, Neely B, Neely ML, Pencina MJ, Kraus WE, et al. Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure. JACC Heart Fail (2014) 2:260–8.10.1016/j.jchf.2013.12.00424952693
14. Lupón J, de Antonio M, Galán A, Vila J, Zamora E, Urrutia A, et al. Combined use of the novel biomarkers high-sensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment. Mayo Clin Proc (2013) 88:234–43.10.1016/j.mayocp.2012.09.01623384388
15. Royston P, Sauerbrei W. Multivariable Model-building: A Pragmatic Approach to Regression Analysis Based on Fractional Polynomials for Modelling Continuous Variables. Chichester, UK: Wiley (2008).
16. Desai AS, Stevenson LW. Rehospitalization for heart failure: predict or prevent? Circulation (2012) 126:501–6.10.1161/CIRCULATIONAHA.112.125435
17. Braunwald E. Biomarkers in heart failure. N Engl J Med (2008) 358:2148–59.10.1056/NEJMra0800239
18. Ky B, French B, Levy WC, Sweitzer NK, Fang JC, Wu AH, et al. Multiple biomarkers for risk prediction in chronic heart failure. Circ Heart Fail (2012) 5:183–90.10.1161/CIRCHEARTFAILURE.111.96502022361079
19. Gaggin HK, Szymonifka J, Bhardwaj A, Belcher A, De Berardinis B, Motiwala S, et al. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. JACC Heart Fail (2014) 2:65–7.10.1016/j.jchf.2013.10.00524622120
20. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 128:e240–327.10.1161/CIR.0b013e31829e8807
21. ®) ST2 assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2. Expert Rev Mol Diagn (2013) 13:13–30.10.1586/erm.12.12823256700
22. Troughton R, Michael Felker G, Januzzi JL, Jr. Natriuretic peptide-guided heart failure management. Eur Heart J (2014) 35:16–24.10.1093/eurheartj/eht463
23. DeBeradinis B, Januzzi JL, Jr. Use of biomarkers to guide outpatient therapy of heart failure. Curr Opin Cardiol (2012) 27:661–8.10.1097/HCO.0b013e3283587c4d22941124
24. Felker GM, Ahmad T, Anstrom KJ, Adams KF, Cooper LS, Ezekowitz JA, et al. Rationale and design of the GUIDE-IT study: guiding evidence based therapy using biomarker intensified treatment in heart failure. JACC Heart Fail (2014) 2:457–65.10.1016/j.jchf.2014.05.007
25. Rogers JK, Pocock SJ, McMurray JJ, Granger CB, Michelson EL, Östergren J, et al. Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-preserved. Eur J Heart Fail (2014) 16:33–40.10.1002/ejhf.2924453096
26. Miller WL, Saenger AK, Grill DE, Slusser JP, Bayes-Genis A, Jaffe AS. Prognostic value of serial measurements of soluble suppression of tumorigenicity 2 and galectin-3 in ambulatory patients with chronic heart failure. J Card Fail (2016) 22:249–55.10.1016/j.cardfail.2015.07.01726277907